Reverse regulation of soluble receptor for advanced glycation end products and proinflammatory factor resistin and S100A12 in Kawasaki disease

Table 3 Serum levels of resistin, S100A12 and soluble receptor for advanced glycation end products (sRAGE) in Kawasaki disease (KD) with or without coronary artery lesions (CALs)

Characteristic		KD with CALs (n= 9)	KD without CALs (n= 31)	P
Boys/girls, number		4/5	18/13	0.000
Age, months		27.1 (20.7)	22.1 (15.6)	0.001
Resistin, 10² ng/ml	Acute stage	0.46 (0.24)	0.36 (0.26)	0.268
	Afebrile stage	0.31 (0.20)	0.22 (0.22) *	0.266
	Subacute stage	0.15 (0.08)** ^▲	0.13 (0.08) **	0.663
S100A12, 10² ng/ml	Acute stage	5.09 (2.78)	5.40 (3.42)	0.804
	Afebrile stage	4.22 (3.29)	4.02 (3.63)	0.883
	Subacute stage	2.52 (3.16)	2.65 (2.53)**	0.899
sRAGE, 10² pg/ml	Acute stage	2.97(1.99)	3.01 (1.92)	0.959
	Afebrile stage	5.93 (3.59)*	5.70 (2.64)**	0.833
	Subacute stage	7.06 (3.88)*	6.77 (2.86)**	0.802

Results are mean (SD) unless stated otherwise. *P < 0.05, **P < 0.01 compared with acute stage; ^▲P < 0.05 compared with group afebrile stage.

ISSN: 1478-6362